TAK-360

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Idiopathic HypersomniaNarcolepsy Type 1

6 competitors in Idiopathic Hypersomnia

#DrugCompanyPhaseTrials

1

Biaxin

AbbVie

Approved

—2

Romazicon

CConrado Roberto Hoffmann Filho

Approved

—3

Sunosi

AAxsome Therapeutics, Inc.

Phase 2

14

Low Sodium Oxybate

SStanford University

Phase 3

25

FT218

AAvadel

Phase 3

16

TAK-360

Takeda

Phase 2

27

ORX750

CCentessa Pharmaceuticals (UK) Limited

Phase 2

2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Idiopathic Hypersomnia2 trials

A Long-term Extension Trial to Evaluate the Safety and Tolerability of TAK-360 in Participants With Selected Central Hypersomnia Conditions

Recruiting·Takeda·Preclinical·NCT07646678·500 enrolled

A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants With Idiopathic Hypersomnia (IH)

Recruiting·Takeda·Phase 2·NCT06812078·96 enrolled

Narcolepsy Type 21 trial

A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding, Adaptive Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants With Narcolepsy Without Cataplexy (NT2)

Recruiting·Takeda·Phase 2·NCT06952699·88 enrolled

Narcolepsy Type 11 trial

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)

Recruiting·Takeda·Phase 2·NCT07633301·92 enrolled

Details

Drug Info

Related News